Regencell Bioscience faces securities fraud lawsuits
Analysis based on 8 articles · First reported May 18, 2026 · Last updated Jun 01, 2026
The securities fraud class action lawsuits and the United States — United States Department of Justice investigation into Regencell Bioscience Holdings have caused its stock price to fall significantly. This event highlights the risks of market manipulation and potential regulatory scrutiny for publicly traded companies, impacting investor confidence in the biotechnology sector.
Multiple law firms, including Glancy Prongay & Murray, the Law Offices of Howard G. Smith, and the The Law Offices of Frank R. Cruz, have filed securities fraud class action lawsuits against Regencell Bioscience Holdings. The lawsuits allege that Regencell Bioscience Holdings failed to disclose its vulnerability to market manipulation, which led to significant financial risk for investors due to stock volatility. Furthermore, Regencell Bioscience Holdings disclosed on October 31, 2025, that the United States — United States Department of Justice is conducting an investigation into the trading of its ordinary shares, requesting documents and communications. This news caused Regencell Bioscience Holdings' stock price to drop by 18.56%. The class period for the lawsuit is between October 28, 2024, and October 31, 2025, with a lead plaintiff deadline of June 23, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard